A literature review to identify factors that determine policies for influenza vaccination

Health Policy

Volumn 119, Issue 6, 2015, Pages 697-708

  Silva, Maria Laura ^a,b   Perrier, Lionel ^a,b,c   Cohen, Jean Marie ^d   Paget, William John ^e   Mosnier, Anne ^d   Späth, Hans Martin ^f  

^a UNIVERSITÉ LUMIÈRE LYON 2   (France)

^b GATE Lyon Saint Etienne   (France)

^c CENTRE LÉON BÉRARD   (France)

^d Open Rome Coordination Nationale des Groupes Régionaux d'Observation de la Grippe   (France)

^e NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

Decision making; Health policy; Influenza vaccination; Policy making

Indexed keywords

FUNDING; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITAL ADMINISTRATOR; HOSPITAL MANAGEMENT; HUMAN; INFLUENZA VACCINATION; MEDICAL DECISION MAKING; MEDICAL INFORMATION; NATIONAL HEALTH INSURANCE; PANDEMIC INFLUENZA; QUALITATIVE RESEARCH; REIMBURSEMENT; REVIEW; INFLUENZA; MANAGEMENT; ORGANIZATION; VACCINATION;

INFLUENZA VACCINE;

DECISION MAKING, ORGANIZATIONAL; HEALTH POLICY; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; POLICY MAKING; QUALITATIVE RESEARCH; VACCINATION;

EID: 84930083086     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2015.04.006     Document Type: Review

References (90)

1. Monto A.S., Ansaldi F., Aspinall R., McElhaney J.E., Montano L.F., Nichol K.L., et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009, 27:5043-5053.
2. Silva M.L., Perrier L., Späth H.-M., Grog I., Mosnier A., Havet N., et al. Economic burden of seasonal influenza B in France during winter 2010-2011. BMC Public Health 2014, 14:56. 10.1186/1471-2458-14-56.
3. Bailey T.M., Haines C., Rosychuk R.J., Marrie T.J., Yonge O., Lake R., et al. Public engagement on ethical principles in allocating scarce resources during an influenza pandemic. Vaccine 2011, 29:3111-3117.
4. Wallinga J., van Boven M., Lipsitch M. Optimizing infectious disease interventions during an emerging epidemic. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:923-928.
5. Rosella L.C., Wilson K., Crowcroft N.S., Chu A., Upshur R., Willison D., et al. Pandemic H1N1 in Canada and the use of evidence in developing public health policies-a policy analysis. Social Science and Medicine 2013, 83:1-9. (1982). 10.1016/j.socscimed.2013.02.009.
6. Timpka T., Eriksson H., Gursky E.A., Nyce J.M., Morin M., Jenvald J., et al. Population-based simulations of influenza pandemics: validity and significance for public health policy. Bulletin of the World Health Organization 2009, 87:305-311. 10.1590/S0042-96862009000400016.
7. Barnitz L., Berkwits M. The health care response to pandemic influenza. Annals of Internal Medicine 2006, 145:135-137.
8. Bryson M., Duclos P., Jolly A., Bryson J. A systematic review of national immunization policy making processes. Vaccine 2010, 28(Suppl 1):A6-A12. 10.1016/j.vaccine.2010.02.026.
9. Duclos P., Ortynsky S., Abeysinghe N., Cakmak N., Janusz C.B., Jauregui B., et al. Monitoring of progress in the establishment and strengthening of national immunization technical advisory groups. Vaccine 2012, 30:7147-7152. 10.1016/j.vaccine.2012.04.015.
10. WHO World Health Organization: fact sheet seasonal influenza (Fact sheet No. 211), WHO Influenza Seas 2009, WHO, http://www.who.int/mediacentre/factsheets/fs211/en/index.html (accessed January 9, 2012).
11. Palache A. Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national public health policies. Vaccine 2011, 29:9459-9466.
12. Miller E. Report from the SAGE working group on influenza vaccines and immunizations 2011, http://www.who.int/influenza_vaccines_plan/resources/lmiller.pdf (accessed February 20, 2014).
13. Beyer W.E.P., McElhaney J., Smith D.J., Monto A.S., Nguyen-Van-Tam J.S., Osterhaus A.D.M.E. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine 2013, 31:6030-6033. 10.1016/j.vaccine.2013.09.063.
14. Jefferson T., Di Pietrantonj C., Al-Ansary L.A., Ferroni E., Thorning S., Thomas R.E. Vaccines for preventing influenza in the elderly (review). Cochrane Database Syst. Rev. 2010, (February (2)):CD004876. 10.1002/1465858.CD004876.pub3.
15. Knottnerus J.A. Influenza vaccination in the elderly: current evidence and uncertainties. Journal of Clinical Epidemiology 2009, 62:675-676. 10.1016/j.jclinepi.2008.10.006.
16. Gatwood J., Meltzer M.I., Messonnier M., Ortega-Sanchez I.R., Balkrishnan R., Prosser L.A. Seasonal influenza vaccination of healthy working-age adults a review of economic evaluations. Drugs 2012, 72:35-48.
17. Ortiz J.R., Englund J.A., Neuzil K.M. Influenza vaccine for pregnant women in resource-constrained countries: a review of the evidence to inform policy decisions. Vaccine 2011, 29:4439-4452.
18. Beck C.R., McKenzie B.C., Hashim A.B., Harris R.C., Zanuzdana A., Agboado G., et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS ONE 2011, 6.
19. Cawley J., Hull H.F., Rousculp M.D. Strategies for implementing school-located influenza vaccination of children: a systematic literature review. Journal of School Health 2010, 80:167-175. 10.1111/j. 1746-1561.2009.00482.x.
20. Newall A.T., Kelly H., Harsley S., Scuffham P.A. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. Pharmacoeconomics 2009, 27:439-450.
21. Burls A., Jordan R., Barton P., Olowokure B., Wake B., Albon E., et al. Vaccinating healthcare workers against influenza to protect the vulnerable-is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine 2006, 24:4212-4221.
22. Luna E.J., Gattas V.L. Effectiveness of the Brazilian influenza vaccination policy, a systematic review. Revista do Instituto de Medicina Tropical de São Paulo 2010, 52:175-181.
23. Turner D., Wailoo A., Nicholson K., Cooper N., Sutton A., Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technology Assessment 2003, 7:1-170. (iii-iv, xi-xiii).
24. Ottenberg A.L., Wu J.T., Poland G.A., Jacobson R.M., Koenig B.A., Tilburt J.C. Vaccinating health care workers against influenza: the ethical and legal rationale for a mandate. American Journal of Public Health 2011, 101:212-216.
25. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 2009, 151:264-269. 10.7326/0003-4819-151-4-200908180-00135.
26. Tamblyn S.E. Pandemic planning in Canada. European Journal of Epidemiology 1994, 10:503-505.
27. Hinman A.R. Quantitative policy analysis and public health policy: a macro and a micro view. American Journal of Preventive Medicine 1997, 13:6-11.
28. Fock R., Bergmann H., Bussmann H., Fell G., Finke E.J., Koch U., et al. Conceptional considerations for a German influenza pandemic preparedness plan. Medical Microbiology and Immunology (Berlin). 2002, 191:191-195.
29. Gensheimer K.F., Fukuda K., Brammer L., Cox N., Patriarca P.A., Strikes R.A. Preparing for pandemic influenza: the need for enhanced surveillance. Vaccine 2002, 20(Suppl 2):S63-S65.
30. Fedson D.S. Preparing for pandemic vaccination: an international policy agenda for vaccine development. Journal of Public Health Policy 2005, 26:4-29.
31. van Genugten M.L.L., Heijnen M.-L.A., Jager J.C. Pandemic influenza and healthcare demand in the Netherlands: scenario analysis. Emerging Infectious Diseases 2003, 9:531-538.
32. Labro M.T., Etiemble J. The strategy against influenza. Revue du Praticien 2010, 60:81-92.
33. Moghadas S.M., Pizzi N.J., Wu J.H., Tamblyn S.E., Fisman D.N. Canada in the face of the 2009 H1N1 pandemic. Influenza and Other Respiratory Viruses 2011, 5:83-88.
34. Maciejewski R., Livengood P., Rudolph S., Collins T.F., Ebert D.S., Brigantic R.T., et al. A pandemic influenza modeling and visualization tool. Journal of Visual Languages and Computing 2011.
35. Kort R., Stuart A.J., Bontovics E. Ensuring a broad and inclusive approach: a provincial perspective on pandemic preparedness. Canadian Journal of Public Health/Revue Canadienne de Sante Publique 2005, 96:409-411.
36. Nicoll A., Ammon A., Amato A., Ciancio B., Zucs P., Devaux I., et al. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. Public Health 2010, 124:14-23.
37. Leask J., Helms C.M., Chow M.Y., Robbins S.C., McIntyre P.B. Making influenza vaccination mandatory for health care workers: the views of NSW Health administrators and clinical leaders. Northwest Public Health Bulletin 2010, 21:243-247.
38. Torda A. Ethical issues in pandemic planning. Medical Journal of Australia 2006, 185:S73-S76.
39. Levine H., Balicer R.D., Laor D., Grotto I. Challenges and opportunities in the Israeli 2009 pandemic influenza vaccination program. Human Vaccines 2011, 7:1077-1082.
40. Kotalik J. Preparing for an influenza pandemic: ethical issues. Bioethics 2005, 19:422-431.
41. Rosner D. Spanish flu, or whatever it is...: the paradox of public health in a time of crisis. Public Health Reports 2010, 125:38-47.
42. Kinlaw K., Barrett D.H., Levine R.J. Ethical guidelines in pandemic influenza: recommendations of the Ethics Subcommittee of the Advisory Committee of the Director, Centers for Disease Control and Prevention. Disaster Medicine and Public Health PreparednessV 3 2009, (Suppl 2):S185-S192.
43. Dehner G. WHO knows best? National and international responses to pandemic threats and the lessons of 1976. Journal of the History of Medicine and Allied Sciences 2010, 65:478-513.
44. Berman P.P., Orenstein W.A., Hinman A.R., Gazmararian J. Stakeholder attitudes toward influenza vaccination policy in the United States. Health Promotion Practice 2010, 11:807-816.
45. Mereckiene J., Cotter S., D'Ancona F., Giambi C., Nicoll A., Levy-Bruhl D., et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Eurosurveillance 2010, 15(44). http://www.who.int/mediacentre/news/notes/2007/np13/en/ (accessed February 22, 2014).
46. Lewis K.K. The pandemic threat: are we prepared?. Issue Brief Mass Health Policy Forum 2006, 1-14.
47. Esposito S., Principi N. Differences in vaccinations in European Union. Human Vaccines 2008, 4:313-315.
48. Barnett D.J., Taylor H.A., Hodge J.G., Links J.M. Resource allocation on the frontlines of public health preparedness and response: report of a summit on legal and ethical issues. Public Health Reports 2009, 124:295-303.
49. Kakkar M., Hazarika S., Zodpey S., Reddy K.S. Influenza pandemic preparedness and response: a review of legal frameworks in India. Indian Journal of Public Health 2010, 54:11-17.
50. French P.E. Enhancing the legitimacy of local government pandemic influenza planning through transparency and public engagement. Public Administration Review 2011, 71:253-264.
51. Ropero-Alvarez A.M., Kurtis H.J., Danovaro-Holliday M.C., Ruiz-Matus C., Andrus J.K. Expansion of seasonal influenza vaccination in the Americas. BMC Public Health 2009, 9:361.
52. Ng S., Wu P., Nishiura H., Ip D.K., Lee E.S., Cowling B.J. An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11. BMC Infectious Diseases 2011, 11:230.
53. Monto A.S. Seasonal influenza and vaccination coverage. Vaccine 2010, 28(Suppl 4):D33-D44.
54. Granstrom M., Voordouw A.C. Registration of influenza vaccines for children in Europe. Vaccine 2011, 29:7572-7575.
55. Ajelli M., Merler S., Pugliese A., Rizzo C. Model predictions and evaluation of possible control strategies for the 2009 A/H1N1v influenza pandemic in Italy. Epidemiology & Infection 2011, 139:68-79.
56. Mereckiene J., Cotter S., Weber T., Nicoll A., D'Ancona F., Lopalco P., et al. Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe. Eurosurveillance 2012, 17:18-27.
57. Chawla R., Sharma R.K., Bhardwaj J.R. Influenza a (H1N1) outbreak and challenges for pharmacotherapy. Indian Journal of Physiology and Pharmacology 2009, 53:113-126.
58. Ampofo W.K., Baylor N., Cobey S., Cox N.J., Daves S., Edwards S., et al. Improving influenza vaccine virus selection report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza and Other Respiratory Viruses 2012, 6:142-150.
59. Johansen K., Nicoll A., Ciancio B.C., Kramarz P. Pandemic influenza a(H1n1) 2009 vaccines in the European Union. Eurosurveillance 2009, 14:12-18.
60. O'Neill E., Donis R.O. Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines. Current Topics in Microbiology and Immunology 2009, 333:83-108.
61. Cho S.H. The optimal composition of influenza vaccines subject to random production yields. Manufacturing & Service Operations Management 2010, 12:256-277.
62. Wu J.T., Wein L.M., Perelson A.S. Optimization of influenza vaccine selection. Operations Research 2005, 53:456-476.
63. Kamradt-Scott A. Changing perceptions of pandemic influenza and public health responses. American Journal of Public Health 2012, 102:90-98.
64. Friede M., Serdobova I., Palkonyay L., Kieny M.P. Technology transfer hub for pandemic influenza vaccine. Vaccine 2009, 27:631-632.
65. Wunderli W., Chappuis S., Wunderli H. World-wide surveillance of influenza. Sozial-und Praventivmedizin 1997, 42(Suppl 2):S83-S87.
66. Orenstein W.A., Schaffner W. Lessons learned: role of influenza vaccine production, distribution, supply, and demand-what it means for the provider. American Journal of Medicine 2008, 121:S22-S27.
67. Gronvall G.K., Borio L.L. Removing barriers to global pandemic influenza vaccination. Biosecurity and Bioterrorism 2006, 4:168-175.
68. Fedson D.S. Vaccine development for an imminent pandemic-why we should worry, what must we do. Human Vaccines 2006, 2:38-42.
69. WHO WHO and international community make progress towards ensuring access of developing countries, WHO Media Cent 2007, WHO, pii: 19700. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19700.
70. Nevel A., Layton C. Influenza vaccine who buys it and who sells it 2005, http://www.rti.org/pubs/laytonwhobuysit.pdf (accessed February 22, 2014).
71. Hodge J.G., O'Connell J.P. The legal environment underlying influenza vaccine allocation and distribution strategies. Journal of Public Health Management and Practice 2006, 12:340-348.
72. Weeramanthri T.S., Robertson A.G., Dowse G.K., Effler P.V., Leclercq M.G., Burtenshaw J.D., et al. Response to pandemic (H1N1) 2009 influenza in Australia-lessons from a state health department perspective. Australian Health Review 2010, 34:477-486.
73. Abelin A., Colegate T., Gardner S., Hehme N., Palache A. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective. Vaccine 2011, 29:1135-1138.
74. Hollingsworth T.D., Klinkenberg D., Heesterbeek H., Anderson R.M. Mitigation strategies for pandemic influenza A: balancing conflicting policy objectives. PLoS Computational Biology 2011, 7:e1001076.
75. Rambhia K.J., Watson M., Sell T.K., Waldhorn R., Toner E. Mass vaccination for the 2009 H1N1 pandemic: approaches, challenges, and recommendations. Biosecurity and Bioterrorism 2010, 8:321-330.
76. Boeker M., Vach W., Motschall E. Google scholar as replacement for systematic literature searches: good relative recall and precision are not enough. BMC Medical Research Methodology 2013, 13:131. 10.1186/1471-2288-13-131.
77. Ringel J.S., Moore M., Zambrano J., Lurie N. Will routine annual influenza prevention and control systems serve the United States well in a pandemic?. Disaster Medicine and Public Health Preparedness 2009, 3(Suppl 2):S160-S165. 10.1097/DMP.0b013e3181ad1833.
78. Tam T., Sciberras J., Mullington B., King A. Fortune favours the prepared mind - A national perspective on pandemic preparedness. Canadian Journal of Public Health/Revue Canadienne de Sante Publique 2005, 96:406-408.
79. H.European Union Health Security Committee, E.Early Warning and Response System Report of the stakeholder consultation on health security in the European Union 2011, European Commission Health and Consumers Directorate-General, Brussels, http://ec.europa.eu/health/preparedness_response/docs/healthsecurity_report_en.pdf.
80. Macher J.T., Springs S.L. Unhealthy technological investment: survey results and policy implications from influenza virus vaccine manufacturers 2013.
81. Muzumdar J.M., Cline R.R. Vaccine supply, demand, and policy: a primer. Journal of American Pharmacists Association 2009, 49:87-99.
82. Schwartz B., Orenstein W.A. Prioritization of pandemic influenza vaccine: rationale and strategy for decision making. Current Topics in Microbiology and Immunology 2009, 333:495-507. 10.1007/978-3-540-92165-3_24.
83. Drummond M., Chevat C., Lothgren M. Do we fully understand the economic value of vaccines?. Vaccine 2007, 25:5945-5957. 10.1016/j.vaccine.2007.04.070.
84. Gazmararian J.A., Orenstein W.A., Wortley P., Buehler J.W., Elon L., Koplan J.P., et al. Preventing influenza: vaccine systems and practices in the southeast. Public Health Reports 2006, 121:684-694.
85. Floret D. Vaccinations: élaboration des recommandations et de leur évolution en France. Annales Pharmaceutiques Françaises 2009, 67:219-223. 10.1016/j.pharma.2009.03.006.
86. Kamradt-Scott A., Lee K. The 2011 pandemic influenza preparedness framework: global health secured or a missed opportunity?. Political Studies 2011, 59:831-847.
87. Ross R. CIDRAP News Indonesia details reasons for withholding H5N1 viruses 2008, CIDRAP, http://www.cidrap.umn.edu/news-perspective/2008/07/indonesia-details-reasons-withholding-h5n1-viruses (accessed October 10, 2014).
88. Morens D.M., Taubenberger J.K., Folkers G.K., Fauci A.S. Pandemic Influenza's 500th anniversary. Clinical Infectious Diseases 2010, 51:1442-1444.
89. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010, 28(Suppl 4):D45-D53.
90. Collin N., Briand S. Influenza vaccine: globalization of public health stakes. Medecine Tropicale (Marseilles) 2009, 69:322.